Zintrexyl-C NDC 59088-180

NDC codes

FDA NDC Directory

Product NDC (as listed)59088-180Labeler and product segments. Claims need a package NDC.

Product NDC at billing width59088-0180Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
59088-180-58	59088018058	60 TABLET in 1 BOTTLE, PLASTIC (59088-180-58)Marketed from Feb 11, 2021

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Zintrexyl-C
Generic name (nonproprietary): ferrous fumarate, folic acid
Active ingredients: Vitamin a acetate — 1500 ug/1Ascorbic acid — 250 mg/1Cholecalciferol — 13.75 ug/1.alpha.-tocopherol acetate, Dl- — 45 mg/1Thiamine mononitrate — 3.25 mg/1Riboflavin — 3.35 mg/1Niacinamide — 22.5 mg/1Pyridoxine hydrochloride — 6 mg/1Folic acid — 500 ug/1Cyanocobalamin — 13 ug/1Biotin — 100 ug/1Pantothenic acid — 15 mg/1Calcium carbonate — 75 mg/1Ferrous fumarate — 9 mg/1Potassium iodide — 25 ug/1Magnesium oxide — 37.5 mg/1Zinc oxide — 15 mg/1Selenium — 30 ug/1Cuprous oxide — 1 mg/1Manganese sulfate — .75 mg/1Chromium nicotinate — 37.5 ug/1Molybdenum — 25 ug/1Potassium chloride — 24.5 mg/1Boron — 25 ug/1
Dosage form: Tablet
Route: Oral
Labeler: PureTek Corporation
Product type: Prescription drug
Marketing category: Unapproved drug (other)
Marketing start: Feb 11, 2021
Listing expires: Dec 31, 2026
Other FDA classes: Analogs/Derivatives (Chemical/Ingredient)Ascorbic Acid (Chemical structure)Calcium (Chemical structure)Divalent (Chemical structure)Decreased Copper Ion Absorption (Physiologic effect)Increased Coagulation Factor Activity (Physiologic effect)Increased Large Intestinal Motility (Physiologic effect)Increased Large Intestinal Motility (Physiologic effect)Inhibition Large Intestine Fluid/Electrolyte Absorption (Physiologic effect)Inhibition Large Intestine Fluid/Electrolyte Absorption (Physiologic effect)Inhibition Small Intestine Fluid/Electrolyte Absorption (Physiologic effect)Magnesium Ion Exchange Activity (Mechanism)Magnetic Resonance Contrast Activity (Mechanism)Nicotinic Acids (Chemical structure)Osmotic Activity (Mechanism)Osmotic Activity (Mechanism)Potassium Compounds (Chemical structure)Stimulation Large Intestine Fluid/Electrolyte Secretion (Physiologic effect)Vitamin A (Chemical structure)Vitamin B 12 (Chemical structure)Vitamin B 6 (Chemical/Ingredient)Vitamin D (Chemical structure)
Identifiers: Product ID 59088-180_f204ced9-4611-0544-e053-2a95a90ac1f3SPL ID f204ced9-4611-0544-e053-2a95a90ac1f3SPL set ID bb1492c5-bfca-d632-e053-2a95a90ad7d1UNII 3LE3D9D6OY, PQ6CK8PD0R, 1C6V77QF41, WR1WPI7EW8, 8K0I04919X, TLM2976OFR, 25X51I8RD4, 68Y4CF58BV, 935E97BOY8, P6YC3EG204, 6SO6U10H04, 19F5HK2737, H0G9379FGK, R5L488RY0Q, 1C4QK22F9J, 3A3U0GI71G, SOI2LOH54Z, H6241UJ22B, T8BEA5064F, W00LYS4T26, A150AY412V, 81AH48963U, 660YQ98I10, N9E3X5056QUPC 0359088180587
Pharmacologic class: Blood Coagulation Factor; Calculi Dissolution Agent; Copper Absorption Inhibitor; Nicotinic Acid; Osmotic Laxative; Paramagnetic Contrast Agent; Potassium Salt; Vitamin A; Vitamin B12; Vitamin B6 Analog; Vitamin C; Vitamin D

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N459088018058 followed by a unit qualifier and the quantity

Package 59088-0180-58. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jan 11, 2023.

Indications (excerpt from the label)

INDICATIONS: Zintrexyl-C TM is indicated for the treatment of iron deficiency anemia and folate deficiency as in extended convalescence, menorrhagia, pregnancy, puberty, excessive blood loss, and advanced age. Also for the treatment of the condition in which iron deficiency and vitamin C deficiency occur together, along with a deficient intake or increased need for B-Complex vitamins in chronic and acute illness, as well as cases of metabolic stress, and in convalescence.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)